VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 8, 2026
Stock Comparison
Eli Lilly and Company vs Pernod Ricard SA
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Eli Lilly and Company
LLY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.
View LLY analysisPernod Ricard SA
RI · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Pernod Ricard SA's moat claims, evidence, and risks.
View RI analysisComparison highlights
- Moat score gap: Pernod Ricard SA leads (75 / 100 vs 66 / 100 for Eli Lilly and Company).
- Segment focus: Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health); Pernod Ricard SA has 3 segments (42.3% in Asia/Rest of the World).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Eli Lilly and Company has 5 moat types across 2 domains; Pernod Ricard SA has 4 across 2.
Primary market context
Eli Lilly and Company
Cardiometabolic Health
Branded cardiometabolic pharmaceuticals (type 2 diabetes, obesity, and related metabolic/cardiovascular conditions; especially incretin therapies)
Global
Patients via prescribers; payers/PBMs; wholesaler & pharmacy channels
Drug developer, manufacturer, and marketer
65.5%
Pernod Ricard SA
Asia/Rest of the World
Premium spirits brand ownership, marketing, and distribution
Asia-Pacific, Africa, and other emerging markets
On-trade, off-trade, distributors, and duty-free operators
Brand owner and local-market route-to-market operator
42.3%
Side-by-side metrics
Moat coverage
Shared moat types
Eli Lilly and Company strengths
Pernod Ricard SA strengths
Segment mix
Eli Lilly and Company segments
Full profile >Cardiometabolic Health
Oligopoly
Oncology
Competitive
Immunology
Competitive
Neuroscience
Competitive
Other
Competitive
Pernod Ricard SA segments
Full profile >Europe
Oligopoly
Americas
Oligopoly
Asia/Rest of the World
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.